Alembic Pharmaceuticals announced an 11% revenue increase in Q3 FY26, reaching ₹1,876 Cr. EBITDA rose by 14% to ₹308 Cr with a 16% margin. The company continues to invest in R&D for future growth, focusing on expanding its branded drugs footprint. Alembic is progressing towards the launch of Pivya™ in the US market during Q4, aiming for sustainable growth and profitability.
Financial Performance in Q3 FY26
Alembic Pharmaceuticals Limited has reported its consolidated financial results for the third quarter and nine months ending December 31, 2025. The company posted strong revenue growth with continued investment in research and development.
Key Financial Highlights
Here are the key financial highlights from the announcement:
- Revenue from operations increased by 11% to ₹1,876 Cr.
- EBITDA increased by 14% to ₹308 Cr.
- EBITDA Margin stood at 16% of revenue.
- Profit Before Exceptional Items and Tax increased by 15% to ₹205 Cr.
- The company recognized a one-time provision of ₹42 Cr towards employee benefits due to changes in the new labor code.
- Reported Profit After Tax, accounting for the one-time provision, was ₹133 Cr.
Management Commentary
Mr. Pranav Amin MD, Alembic Pharmaceuticals Limited, stated, “Our Q3 performance underscores the sustained momentum across our businesses supported by consistent execution, continued focus on profitability and operating rhythm. We further strengthened our presence in Australia, Canada, Europe, the USA and other key markets delivering an overall growth of 11%. Our pre-R&D EBITDA margin at 25% remains healthy. We continued to invest around 9% of revenue in R&D to build a robust pipeline for future growth.”
Operational Performance
The company highlighted the following operational achievements:
- India Branded Business delivered 6% YoY growth, reaching ₹652 Cr in revenue for the quarter (Q3).
- Gynaecology, Ophthalmology and Animal healthcare segments supported the growth for the quarter.
- US Generics grew by 6% to ₹553 Cr for the quarter (Q3).
- Ex-US International Generics grew by 36% to ₹406 Cr for the quarter (Q3).
Revenue Summary
Here is a summary of revenue from operations:
| Particulars | Q3 FY25 | Q3 FY26 | % Change | 9M FY26 | 9M FY25 | % Change |
| Formulation | ||||||
| India | 614 | 652 | 6% | 1890 | 1795 | 5% |
| USA | 521 | 553 | 6% | 1642 | 1449 | 13% |
| Ex- US | 299 | 406 | 36% | 1126 | 868 | 30% |
| API | 259 | 264 | 2% | 839 | 791 | 6% |
| Total | 1,693 | 1,876 | 11% | 5,497 | 4,902 | 12% |
Earnings Call Information
Alembic Pharmaceuticals will host an investor call on February 5, 2026, at 4:30 pm IST.
Source: BSE
